Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 22 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Pembrolizumab for Advanced NSCLC and PS 2-3RecruitingNCT05589818Phase 2
- Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2
- Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerRecruitingNCT05588219Phase 2
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsRecruitingNCT05584670Phase 1/2
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Safety and Efficacy of RX-af01 Combined With PD-1 AntibodyRecruitingNCT05576961Phase 1/2
- SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingNCT05576480Phase 2
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingNCT05576389Phase 2
- SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerRecruitingNCT05570825Phase 2
- Pembro With Radiation With or Without OlaparibRecruitingNCT05568550Phase 2
- Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabRecruitingNCT05568212Phase 2
- Pembrolizumab Plus Radiotherapy for Advanced Renal CancerRecruitingNCT05567588Phase 2
- Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)RecruitingNCT05563558Phase 2
- Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingNCT05562297Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
- The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal CancerRecruitingNCT05555888Phase 2
- Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial CancerNot yet recruitingNCT05550558Phase 2
- Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)RecruitingNCT05549297Phase 3
- Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaNot yet recruitingNCT05540275Phase 2
- Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable MelanomaNot yet recruitingNCT05539118Phase 1/2
- Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerRecruitingNCT05538091Phase 2
- A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid TumoursNot yet recruitingNCT05537051Phase 1
- The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)RecruitingNCT05536102Phase 2
- Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCRecruitingNCT05533892Phase 1
- Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective StudyNot yet recruitingNCT05532527Not applicable
- Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingNCT05532059Phase 2
- PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.Not yet recruitingNCT05530200Phase 2
- Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsNot yet recruitingNCT05527821Phase 2
- A Single-arm Exploratory Study of Neoadjuvant TherapyRecruitingNCT05527808Not applicable
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingNCT05526989Phase 2
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingNCT05526924Phase 1
- Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse AstrocytomaNot yet recruitingNCT05518994Phase 2
- GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)Not yet recruitingNCT05518318Phase 3
- Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05515315Phase 2
- Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral MelanomaRecruitingNCT05512481Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaRecruitingNCT05512351Phase 2
- Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical CancerRecruitingNCT05511623Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNot yet recruitingNCT05502991Phase 2
- Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
- The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung CancerNot yet recruitingNCT05496166Phase 3
- Neoadjuvant PD-1 Blockade in Resectable Merkel Cell CarcinomaRecruitingNCT05496036Phase 2
- Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05495152Phase 3
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Phase 2
- Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal CancerRecruitingNCT05493683Phase 2
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingNCT05493566Early Phase 1
- START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerRecruitingNCT05492682Phase 1
- Nivolumab-ipilimumab and Chemoradiation for Cervical CancerRecruitingNCT05492123Phase 2
- Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingNCT05491226Phase 2
- Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerRecruitingNCT05491083Phase 1/2
- A Phase II Study of CRT Combined With QL1706 in ESCC PatientsRecruitingNCT05490719Phase 2
- Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT05490485Phase 2
- A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Phase 3
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingNCT05488353Phase 4
- A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.RecruitingNCT05487391Phase 3
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2
- Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With OligometastasesNot yet recruitingNCT05484583Phase 2
- Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line TreatmentNot yet recruitingNCT05484375Phase 2
- Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal CancerNot yet recruitingNCT05484024Phase 2/3
- Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsRecruitingNCT05483400Phase 2
- A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingNCT05482568Phase 1/2
- Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal CancerNot yet recruitingNCT05479240Phase 2
- Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal TypeRecruitingNCT05477264Phase 2
- Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)RecruitingNCT05475171Phase 2
- A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesRecruitingNCT05473156Phase 1/2
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
- PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced MelanomaRecruitingNCT05466474Phase 2
- First-line Replacement Maintenance of Envafolimab in Advanced NSCLCNot yet recruitingNCT05465733Phase 2
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic CancerRecruitingNCT05462496Phase 2
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)RecruitingNCT05451043Phase 2
- Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal CancerRecruitingNCT05450029Phase 2
- Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaRecruitingNCT05448885Phase 2
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
- QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerRecruitingNCT05446883Phase 3
- Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCCRecruitingNCT05446467Phase 2
- Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder CancerNot yet recruitingNCT05445648Phase 2
- A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical CancerNot yet recruitingNCT05444374Phase 2
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT05444088Phase 1/2
- Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC PatientsRecruitingNCT05443646Phase 2
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid TumorsNot yet recruitingNCT05442996Phase 1
- Durvalumab and Tremelimumab in Resectable HCCRecruitingNCT05440864Phase 2
- A Study of YL201 in Patients With Advanced Solid TumorsRecruitingNCT05434234Phase 1/2
- Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05431764Phase 2
- AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian CancerRecruitingNCT05430906Phase 2
- Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung CancerRecruitingNCT05430009Phase 1
- Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）RecruitingNCT05429463Phase 3
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingNCT05428007Phase 2
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingNCT05422794Phase 1
- A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck CancerRecruitingNCT05420948Phase 2
- Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal CarcinomaRecruitingNCT05420597Phase 2
- Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal CancerRecruitingNCT05420584Phase 2
- A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid TumorsRecruitingNCT05417321Phase 1/2